Immunocore Holdings
IMCR· Manufacturing· Fiscal year ends in December
Bahija Jallal, Ph.D. is the CEO of Immunocore Holdings and was paid $10.9M in FY2025 (Dec), down 15%.
Executives4
See all- 1Bahija Jallal, Ph.D.Chief Executive OfficerFY2025
- 2Travis CoyChief Financial OfficerFY2025
- 3David Berman, M.D., Ph.D.Former Executive Vice President, Head of Research & DevelopmentFY2025
- 4Tina St. LegerChief Human Resources OfficerFY2024
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allImmunocore Holdings paid its 3 named executives $20.3M in total in FY2025 (Dec). CEO Bahija Jallal, Ph.D. was paid $10.9M of that.
| Name | |||
|---|---|---|---|
| Bahija Jallal, Ph.D.Chief Executive Officer | |||
| Travis CoyChief Financial Officer | Not disclosed | Not disclosed | |
| David Berman, M.D., Ph.D.Former Executive Vice President, Head of Research & Development | |||
| Tina St. LegerChief Human Resources Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe FY2025 (Dec) proxy of Immunocore Holdings names 20 peer companies for pay. Among Immunocore Holdings and these peers, CEO pay was 4th highest of 7 and total shareholder return was 4th highest of 7.
4th highest of 7in Immunocore Holdings and its pay peers, FY2025 (Dec) by CEO pay:
4th highest of 7in Immunocore Holdings and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Roy S. Herbst, M.D., Ph.D.Director · 4 yr on the boardIndependent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 16, 2026 | FY2025 |
| Annual report | 10-K | Feb 25, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 4, 2025 | FY2024 |
| Annual report | 10-K | Feb 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 12, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |